AFFiRiS AG

AFFiRiS and Frontier Biotechnologies announce license agreement for AFFITOPE(R)AT04, an active immunotherapy targeting PCSK9 to treat hypercholesterolemia, in Greater China

AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases

AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology

AFFiRiS AG: Positive preclinical in vivo results with AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease to be presented at the 16th Annual Huntington’s Disease Therapeutics Conference

AFFiRiS announces late-breaking presentation of clinical PD01 data in Parkinson’s disease patients at the MDS Virtual Congress

AFFiRiS announces publication in Movement Disorders Journal of positive clinical results of a Phase 1 trial in early Multiple System Atrophy

The Lancet Neurology publishes positive results of AFFiRiS’ Phase 1 trial with PD01A in Parkinson’s disease patients

Neurobiology of Disease publishes encouraging preclinical results of AFFiRiS’ antibody mAB C6-17 to treat Huntington’s disease

World Parkinson’s Day: AFFiRiS developing PD01 to treat Parkinson’s disease, a major unmet medical need

AFFiRiS granted new patent in China for treating Parkinson’s disease

AFFiRiS Announces FDA Response to its pre-IND Submission for Phase 2 trial with AFFITOPE PD01 in Early Parkinson’s Disease Patients

AFFiRiS announces Phase 2 study in Parkinson’s and new focus on neurodegenerative diseases